-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250

Benzinga·07/24/2026 18:08:53
Listen to the news
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $225 to $250.